Skip to main content

Table 5 Description of overall cardiovascular toxicity observed with pazopanib treatment

From: Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Entire Study Population (n) 35
Any CV toxicity 24 (69%)
Any CV toxicity excluding hypertension 12 (34%)
Grade 1 QTc prolongation 6 (17%)
Grade 2 QTc prolongation 2 (6%)
Grade 3 heart failure 1 (3%)
Grade 5 heart failure 1 (3%)
Grade 3 atrial flutter 1 (3%)
Grade 3 peripheral ischemia 1 (3%)
Grade 2 hypertension 3 (9%)
Grade 3 hypertension 17 (49%)
  1. n number, CV cardiovascular, QTc corrected QT interval. Refer to Table 1 for grading definitions. Results displayed as number of patients (% of all study patients)